By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Indian contract research organization GVK Biosciences said on Monday that it has entered into a drug screening deal with the Moulder Center for Drug Discovery Research at Temple University.

The multi-year agreement calls for GVK Bio to validate targets and identify and optimize small molecules in specific therapeutic areas, such as cardiovascular, metabolic, and central nervous system disorders.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.